ConductScience.org, home

Paper39366294

Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets.

Kehmann L and 5 others. ESMO Open, 2024. Cited by 17 papers, by iCite.

Cite this record

ConductScience Library. Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets. Papers, record 39366294. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39366294

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets.
PubMed
Journal
ESMO Open
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
2.15, provisional
iCite
Revised in PubMed
2026-09-23
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kehmann LL
2Jördens MM
3Loosen SHS H
4Luedde TT
5Roderburg CC
6Leyh CC

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biliary Tract NeoplasmsMajor topic
Molecular Targeted TherapyMajor topic
Humans
Antineoplastic Agents

References109

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124681130Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.J Hepatol2014https://conductscience.org/library/papers/24681130PubMed
232380538Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.Blood Adv2020https://conductscience.org/library/papers/32380538PubMed
329850653Landscape of Microsatellite Instability Across 39 Cancer Types.JCO Precis Oncol2017https://conductscience.org/library/papers/29850653PubMed
427829276Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency.Chin Clin Oncol2016https://conductscience.org/library/papers/27829276PubMed
537870536Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.J Clin Oncol2024https://conductscience.org/library/papers/37870536PubMed
631300360Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.Lancet Gastroenterol Hepatol2019https://conductscience.org/library/papers/31300360PubMed
734656226
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Lancet Oncol2021https://conductscience.org/library/papers/34656226PubMed
832223935TRK inhibitors in TRK fusion-positive cancers.Ann Oncol2019https://conductscience.org/library/papers/32223935PubMed
926258846Genomic spectra of biliary tract cancer.Nat Genet2015https://conductscience.org/library/papers/26258846PubMed
1024185513Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.Nat Genet2013https://conductscience.org/library/papers/24185513PubMed
1125503476Determining the fate of hepatic cells by lineage tracing: facts and pitfalls.Hepatology2015https://conductscience.org/library/papers/25503476PubMed
1232416072Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020https://conductscience.org/library/papers/32416072PubMed
1322180306Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.Oncologist2012https://conductscience.org/library/papers/22180306PubMed
1427095655Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016https://conductscience.org/library/papers/27095655PubMed
1536497187FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?Cells2022https://conductscience.org/library/papers/36497187PubMed
1638870977
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
Lancet Gastroenterol Hepatol2024https://conductscience.org/library/papers/38870977PubMed
1724309328BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.Mod Pathol2014https://conductscience.org/library/papers/24309328PubMed
1830056163Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.J Thorac Oncol2018https://conductscience.org/library/papers/30056163PubMed
1912063950Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.Hepatogastroenterology2002https://conductscience.org/library/papers/12063950PubMed
2030882996Anatomical, histomorphological and molecular classification of cholangiocarcinoma.Liver Int2019https://conductscience.org/library/papers/30882996PubMed

See all 109 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
42698384Next Generation Sequencing for the Differentiation of Benign and Malignant Biliary Strictures.Liver Int2026https://conductscience.org/library/papers/42698384PubMed
42514220Choosing the Platinum Partner in Advanced Biliary Tract Cancer: A Propensity Score-Matched Real-World Comparison of Gemcitabine Plus Carboplatin Versus Gemcitabine Plus Cisplatin.Life (Basel)2026https://conductscience.org/library/papers/42514220PubMed
42512329Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42512329PubMed
42157316Safety and efficacy of PD-1/PD-L1 inhibitors combined with albumin-bound paclitaxel and fluorouracil-based agents as second-line therapy in biliary tract cancers.World J Surg Oncol2026https://conductscience.org/library/papers/42157316PubMed
41897384Inhibition of Glutamate Dehydrogenase as a Potential Strategy to Modulate Intrahepatic Cholangiocarcinoma Cell Metabolism.Biomolecules2026https://conductscience.org/library/papers/41897384PubMed
41783112Health-related quality of life in biliary tract cancer clinical trials. The current state and future directions.ESMO Gastrointest Oncol2026https://conductscience.org/library/papers/41783112PubMed
41694497Twenty-year temporal trends, risk profiles, and prognostic value of clinicopathological features in gallbladder cancer following cholecystectomy.World J Gastroenterol2026https://conductscience.org/library/papers/41694497PubMed
41652428Circulating tumor DNA-guided early detection and minimal residual disease monitoring in pancreatic and biliary cancers: evidence, barriers, and opportunities.World J Surg Oncol2026https://conductscience.org/library/papers/41652428PubMed
41229525Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network.Ther Adv Med Oncol2025https://conductscience.org/library/papers/41229525PubMed
41212690Effectiveness of Chemotherapy Plus Immunotherapy and Molecular Alterations in Advanced Biliary Tract Cancer: Real-World Evidence From a Single-Center Australian Cohort.Cancer Control2025https://conductscience.org/library/papers/41212690PubMed
41158219Primary signet-ring cell carcinoma of the bile duct: clinical characteristics, survival comparison with cholangiocarcinoma, and SEER-based prognostic nomograms.Transl Cancer Res2025https://conductscience.org/library/papers/41158219PubMed
40940908Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?Cancers (Basel)2025https://conductscience.org/library/papers/40940908PubMed
40836103Novel Biopsy Gun Impacts Biopsy Sample Quality and Quantity.Cardiovasc Intervent Radiol2025https://conductscience.org/library/papers/40836103PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
FGFR22263PubTator's text mininghttps://conductscience.org/library/genes/2263NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39366294

GET https://conductscience.org/api/papers/v1/39366294/references?page=2